Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Few previous studies focused on the neoadjuvant treatments of upper urinary or bladder
cancer, especially chemotherapy combined with immunotherapy, however, available data of
retrospective studies showed this neoadjuvant treatment model might benefit patients. So This
prospective Phase II clinical trial was designed to explore the efficacy of chemotherapy
combined with PD-1 inhibitor as neoadjuvant therapy in upper urinary and muscle-invasive
bladder urothelial carcinoma, then to improve the rate of complete pathological remission,
survival and provide medical evidence.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences Jianzhong Shou